Intocell

About:

Intocell is a biotechnology company that develops antibody drug conjugate (ADC) platform technologies.

Top Investors: Atinum Partners, Stonebridge Capital, Seoul Investment Partners, DA Value Investment, KNet Investment Partners

Description:

Intocell is a biotechnology company that develops an antibody-drug conjugate platform for the R&D and commercialization of biopharmaceuticals. Intocell creates protein-drug complexes, antibody-drug complexes, and other complexes with their own linkers and drugs.

Total Funding Amount:

35B KRW

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Daejeon, Taejon-jikhalsi, South Korea

Founded Date:

2015-01-01

Founders:

Park Tae-gyo

Number of Employees:

1-10

Last Funding Date:

2021-01-04

IPO Status:

Private

Industries: